The Administrative Core is composed of Cancer Center Administration and Senior Leadership of the Sidney Kimmel Comprehensive Cancer Center (SKCCC). The SKCCC Administration's purposes are to facilitate the overall planning, management and organization of the activities of the SKCCC, and to provide the support necessary to achieve and maintain the highest standards of cancer research excellence at the SKCCC. Administration is vital in assuring that the SKCCC achieves its goals and objectives and complies with NCI guidelines for Cancer Center Support Grants (CCSG). These goals are accomplished through an administrative infrastructure that enables streamlined and effective assistance to the Director, Senior Leaders, Program Leaders, Advisory Groups, Core Directors/Managers and general membership. SKCCC Administration provides the centralized management of resources and services required for the SKCCC's research activities, fiscal management and reporting functions. Coordinated activities include: participation in SKCCC governance and decision-making processes; representation of the SKCCC within the institution; oversight and management of CCSG relevant activities, including planning and evaluation oversight of Cores; faculty recruitment support; and management of the membership process and data, space, budgeting and finances, and the CCSG application. SKCCC Senior Leadership is responsible for overall planning and operational activities, administrative and management functions that support SKCCC research, and all scientific Program functions as described in detail throughout this CCSG application. The overall responsibility for planning and operation of research rests with the Director of the SKCCC, William G. Nelson, M.D., Ph.D. Dr. Nelson has carefully assembled a highly cohesive and dynamic Senior Leadership team with a strong commitment to the goals, values and priorities of the SKCCC. The Deputy Director and Associate Directors (ADs) have broad responsibilities and work with the Director to plan scientific direction with particular emphasis on Program interaction and translational research. The Deputy Director and ADs have significant oversight responsibilities for the Research Programs and in research training, education, community programs and outreach. Their collective success is evidenced by new strategic initiatives, evolution of Programs, development of Cores, increased transdisciplinary collaboration along the translational pipeline and, in particular, the impact on the SKCCC catchment area. They are continuously focused on the priorities of the SKCCC, including understanding and addressing cancer disparities. SKCCC leadership includes the Director, Deputy Director (Elizabeth M. Jaffee, M.D.), an AD for Clinical Research (Michael A. Carducci, M.D.), an AD for Population Sciences (John D. Groopman, Ph.D.), an AD for Shared Resources (Robert A. Casero, Ph.D.), an AD for Laboratory Research (Kenneth Kinzler, Ph.D.), an AD for Research Training and Education (Ben Park, M.D., Ph.D.), and an AD for Administration (Rosalie W ollett).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006973-54
Application #
9278330
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-05-01
Budget End
2018-04-30
Support Year
54
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Woodard, Lauren E; Dennis, Cindi L; Borchers, Julie A et al. (2018) Nanoparticle architecture preserves magnetic properties during coating to enable robust multi-modal functionality. Sci Rep 8:12706
Shrestha, Eva; White, James R; Yu, Shu-Han et al. (2018) Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. J Urol 199:161-171
Gordy, James T; Luo, Kun; Francica, Brian et al. (2018) Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3?-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons. J Immunother 41:181-189
El-Diwany, Ramy; Soliman, Mary; Sugawara, Sho et al. (2018) CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humans. Sci Adv 4:eaat0843
Kyker-Snowman, Kelly; Erlanger Avigdor, Bracha; Nasim, Mansoor et al. (2018) A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing. Breast Cancer Res Treat 170:425-430
Christenson, Eric S; Antonarakis, Emmanuel S (2018) PARP inhibitors for homologous recombination-deficient prostate cancer. Expert Opin Emerg Drugs 23:123-133
Ambinder, Richard F (2018) A viral protein kinase drug target for tumors? J Clin Invest 128:2197-2198
Lee, Alice J; Montgomery, Madeline C; Patel, Rupa R et al. (2018) Improving Insurance and Health Care Systems to Ensure Better Access to Sexually Transmitted Disease Testing and Prevention. Sex Transm Dis 45:283-286
Bharathy, Narendra; Berlow, Noah E; Wang, Eric et al. (2018) The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma. Sci Signal 11:
McGrath-Morrow, Sharon A; Ndeh, Roland; Helmin, Kathryn A et al. (2018) DNA methylation regulates the neonatal CD4+ T-cell response to pneumonia in mice. J Biol Chem 293:11772-11783

Showing the most recent 10 out of 2393 publications